Results 191 to 200 of about 154,096 (287)

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary. [PDF]

Immunotherapy
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Carroll H, Naik H, Gaudreault F, Meyers A, Musselli C, Franchimont N, Barbey C.   +17 more
europepmc   +1 more source

Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus. [PDF]

Lupus
Lu G, Brown LS, Chong BF.
europepmc   +1 more source

Frequency of Systemic Lupus Erythematosus in Cutaneous Lupus Erythematosus [PDF]

Journal of Medical Science And clinical Research, 2017
openaire   +1 more source

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary. [PDF]

Immunotherapy
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth V, Huang X, Carroll H, Meyers A, Musselli C, Franchimont N, Barbey C.   +11 more
europepmc   +1 more source

Update on cutaneous lupus erythematosus

Indian Journal of Dermatology, Venereology, and Leprology, 2012
openaire   +3 more sources

High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus

Experimental Dermatology, 2018
J. Wenzel, A. Landmann, Gero Vorwerk, A. Kuhn   +3 more
semanticscholar   +1 more source

Do Steroid Hormones Have an Important Role on Cutaneous Lupus Physiopathology? [PDF]

, 2015
Brasileiro, A, Campos, S, Fidalgo, A
core   +2 more sources

Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials. [PDF]

PLoS One
Yin J, Hou Y, Wang C, Qin C.
europepmc   +1 more source

Cutaneous vasculitis in systemic lupus erythematosus: epidemiology and risk factors over a 20-year follow-up. [PDF]

Rheumatology (Oxford)
Saleh A, Yee CS, Acquah A, Gordon C, Reynolds JA.   +4 more
europepmc   +1 more source